Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies
Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies
复制标题
DOI：
10.1016/j.bpg.2015.01.002
复制
发表时间：
2015-04-01
影响因子：
3.2
通讯作者：
Vogel, A.
中科院分区：
文献类型：
--
作者：
Schweitzer, N.;Vogel, A.
胆管癌（CCA）是罕见的肝脏肿瘤，预后较差。无法切除的肿瘤或转移性疾病患者的标准治疗是吉西他滨和顺铂的联合化疗 (CT)。抑制 EGFR、VEGF、MEK 等的靶向疗法在 CCA 中得到了广泛测试，但迄今为止，来自随机和非随机试验的现有数据并不能证明小分子在临床试验之外的应用是合理的。在临床实践中，许多患者在吉西他滨/顺铂失败后接受二线CT，尽管迄今为止没有证据支持二线CT。本综述总结了当前的化疗方案和正在进行的研究，包括常规化疗和靶向治疗。 (C) 2015 Elsevier Ltd. 保留所有权利。
Cholangiocarcinomas (CCA) are rare tumors of the liver with poor prognosis. The standard of care in patients with unresectable tumors or metastatic disease is combination chemotherapy (CT) with gemcitabine and cisplatin. Targeted therapies inhibiting EGFR, VEGF, MEK and others are broadly tested in CCA but to date, the existing data from randomized and nonrandomized trials do not justify the application of small molecules outside of clinical trials. In clinical practice, many patients receive second-line CT after failure of gemcitabine/cisplatin, although there is so far no evidence to support second-line CT. This review summarizes current chemotherapy protocols and ongoing studies, including conventional chemotherapy and targeted therapies. (C) 2015 Elsevier Ltd. All rights reserved.